Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing
Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing
Telomir製藥以每股7美元的價格在無認購權、受限普通股交易中籌集了100萬美元 - 提交文件
On December 9, 2024, Telomir entered into a Stock Purchase Agreement with a certain accredited investor, pursuant to which the Company issued 142,857 shares of common stock at a price of $7 per share for a total of $1 million, a 20% premium to the closing price of the Company's common stock on the date of the transaction.
2024年12月9日，Telomir與某位合格投資者簽訂了股票購買協議，根據該協議，公司以每股7美元的價格發行了142,857股普通股，總額爲100萬美元，比交易當日公司普通股的收盤價高出20％。
The transaction did not involve the issuance of any warrants. This transaction follows a $5 million non-dilutive line of credit extended to the Company earlier this year by the same accredited investor, which remains undrawn to date.
該交易不涉及任何認股權證的發行。該交易是在同一合格投資者於今年早些時候向公司提供500萬美元的非攤薄信貸額度之後進行的，該信貸額度迄今仍未提取。
資訊熱榜
更新時間